These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20702618)

  • 21. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.
    Lee LY; Schaffer PA
    J Virol; 1998 May; 72(5):4250-64. PubMed ID: 9557715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.
    Gaston DC; Odom CI; Li L; Markert JM; Roth JC; Cassady KA; Whitley RJ; Parker JN
    PLoS One; 2013; 8(11):e81768. PubMed ID: 24312353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
    Kanai R; Tomita H; Hirose Y; Ohba S; Goldman S; Okano H; Kawase T; Yazaki T
    Hum Gene Ther; 2007 Jan; 18(1):63-73. PubMed ID: 17238803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy.
    McKie EA; MacLean AR; Lewis AD; Cruickshank G; Rampling R; Barnett SC; Kennedy PG; Brown SM
    Br J Cancer; 1996 Sep; 74(5):745-52. PubMed ID: 8795577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A proautophagic antiviral role for the cellular prion protein identified by infection with a herpes simplex virus 1 ICP34.5 mutant.
    Korom M; Wylie KM; Wang H; Davis KL; Sangabathula MS; Delassus GS; Morrison LA
    J Virol; 2013 May; 87(10):5882-94. PubMed ID: 23487467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals.
    Mohr I; Sternberg D; Ward S; Leib D; Mulvey M; Gluzman Y
    J Virol; 2001 Jun; 75(11):5189-96. PubMed ID: 11333900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins.
    Harland J; Dunn P; Cameron E; Conner J; Brown SM
    J Neurovirol; 2003 Aug; 9(4):477-88. PubMed ID: 12907392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.
    Broberg EK; Peltoniemi J; Nygårdas M; Vahlberg T; Röyttä M; Hukkanen V
    J Virol; 2004 Dec; 78(23):13139-52. PubMed ID: 15542666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
    Chung RY; Saeki Y; Chiocca EA
    J Virol; 1999 Sep; 73(9):7556-64. PubMed ID: 10438845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ICP34.5-dependent and -independent activities of salubrinal in herpes simplex virus-1 infected cells.
    Bryant KF; Macari ER; Malik N; Boyce M; Yuan J; Coen DM
    Virology; 2008 Sep; 379(2):197-204. PubMed ID: 18684481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
    Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
    J Virol; 2017 May; 91(10):. PubMed ID: 28250120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the DR2 repeat array in the regulation of the ICP34.5 gene promoter of herpes simplex virus type 1 during productive infection.
    Martin DW; Weber PC
    J Gen Virol; 1998 Mar; 79 ( Pt 3)():517-23. PubMed ID: 9519830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interplay between Autophagy and Herpes Simplex Virus Type 1: ICP34.5, One of the Main Actors.
    Ripa I; Andreu S; López-Guerrero JA; Bello-Morales R
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells.
    Fasullo M; Burch AD; Britton A
    Cell Cycle; 2009 Jul; 8(14):2194-7. PubMed ID: 19502787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rethinking herpes simplex virus: the way to oncolytic agents.
    Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
    Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.